Sperm associated antigen 9 promotes oncogenic KSHV-encoded interferon regulatory factor-induced cellular transformation and angiogenesis by activating the JNK/VEGFA pathway

Wan Li,Fei Wang,Jiale Shi,Qi Feng,Yuheng Chen,Xiaoyu Qi,Cong Wang,Hongmei Lu,Zhongmou Lu,Xuemei Jia,Qin Yan,Shou-Jiang Gao,Chun Lu
DOI: https://doi.org/10.1371/journal.ppat.1008730
IF: 7.464
2020-08-10
PLoS Pathogens
Abstract:Kaposi's sarcoma (KS), caused by Kaposi's sarcoma-associated herpesvirus (KSHV), is a highly angioproliferative disseminated tumor of endothelial cells commonly found in AIDS patients. We have recently shown that KSHV-encoded viral interferon regulatory factor 1 (vIRF1) mediates KSHV-induced cell motility (PLoS Pathog. 2019 Jan 30;15(1):e1007578). However, the role of vIRF1 in KSHV-induced cellular transformation and angiogenesis remains unknown. Here, we show that vIRF1 promotes angiogenesis by upregulating sperm associated antigen 9 (SPAG9) using two <em>in vivo</em> angiogenesis models including the chick chorioallantoic membrane assay (CAM) and the matrigel plug angiogenesis assay in mice. Mechanistically, vIRF1 interacts with transcription factor Lef1 to promote SPAG9 transcription. vIRF1-induced SPAG9 promotes the interaction of mitogen-activated protein kinase kinase 4 (MKK4) with JNK1/2 to increase their phosphorylation, resulting in enhanced VEGFA expression, angiogenesis, cell proliferation and migration. Finally, genetic deletion of <em>ORF</em>-<em>K9</em> from KSHV genome abolishes KSHV-induced cellular transformation and impairs angiogenesis. Our results reveal that vIRF1 transcriptionally activates <em>SPAG9</em> expression to promote angiogenesis and tumorigenesis via activating JNK/VEGFA signaling. These novel findings define the mechanism of KSHV induction of the SPAG9/JNK/VEGFA pathway and establish the scientific basis for targeting this pathway for treating KSHV-associated cancers.Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded viral interferon regulatory factor 1 (vIRF1) is essential for KSHV-induced angiogenesis and tumorigenesis, but the underlying mechanism has not been elucidated. Sperm associated antigen 9 (SPAG9) is a well-characterized oncoprotein, highly expressed in a variety of human cancer. However, whether SPAG9 could act as a promoter of KS development has not been investigated. Here, we reveal that vIRF1 enhances SPAG9 transcription by forming a transcription factor complex with Lef1. vIRF1-induced SPAG9 upregulation promotes the interaction of mitogen-activated protein kinase kinase 4 (MKK4) with JNK together leading to enhanced JNK phosphorylation. Activation of the JNK pathway induces VEGFA expression, contributing to KSHV-induced cellular transformation and angiogenesis. In summary, this work discovers a novel mechanism of vIRF1 induction of angiogenesis and tumorigenesis, and reveals SPAG9/JNK/VEGFA pathway as a potential target for KS therapy.
microbiology,virology,parasitology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to reveal the mechanism by which viral interferon regulatory factor 1 (vIRF1) encoded by Kaposi's sarcoma - associated herpesvirus (KSHV) promotes cell transformation and angiogenesis by activating sperm - associated antigen 9 (SPAG9)/JNK/VEGFA signaling pathway. Specifically, the study aims to answer the following questions: 1. **The role of vIRF1 in KSHV - induced cell transformation and angiogenesis**: Although it is known that vIRF1 plays an important role in KSHV - induced cell migration, the specific mechanism in cell transformation and angiogenesis remains unclear. 2. **The role of SPAG9 in KSHV infection**: SPAG9 is a known oncoprotein, but its role in KSHV infection and the development of Kaposi's sarcoma (KS) has not been defined. 3. **How vIRF1 regulates the expression of SPAG9**: The study explored whether vIRF1 enhances SPAG9 transcription by forming a complex with the transcription factor Lef1. 4. **The significance of the SPAG9/JNK/VEGFA pathway in KSHV - related malignancies**: The study evaluated the role of this pathway in KSHV - induced cell transformation, proliferation, migration and angiogenesis, and explored its potential as a therapeutic target. ### Main findings - **vIRF1 enhances SPAG9 transcription by binding to Lef1**: vIRF1 forms a complex with Lef1 and binds to the SPAG9 promoter region, thereby enhancing SPAG9 expression. - **SPAG9 promotes the interaction between MKK4 and JNK1/2**: SPAG9 up - regulated by vIRF1 promotes the binding between MKK4 and JNK1/2, leading to an increase in JNK1/2 phosphorylation. - **JNK1/2 activates VEGFA expression**: The activated JNK1/2 pathway enhances VEGFA expression, which in turn promotes angiogenesis, cell proliferation and migration. - **Inhibition of the JNK pathway can reduce vIRF1 - induced cell behaviors**: After treatment with the JNK inhibitor SP600125, vIRF1 - induced cell proliferation, migration and angiogenesis are all inhibited. - **vIRF1 deletion affects KSHV - induced cell transformation and angiogenesis**: Deletion of ORF - K9 (encoding vIRF1) in the KSHV genome eliminates the KSHV - induced cell transformation ability and weakens angiogenesis. ### Conclusion This study shows that vIRF1 promotes KSHV - induced cell transformation and angiogenesis by transcriptionally activating SPAG9 and then activating the JNK/VEGFA pathway. These findings not only reveal a new mechanism of KSHV - induced tumorigenesis, but also provide potential targets for the development of treatment methods for KSHV - related cancers.